PharmTech AI Pulse Check panelists explain why attribution, audit trails, and sign-off matter more than AI watermark detection for GxP quality teams.
|Articles|September 25, 2017
GEMU 567 BioStar® Control Valve
Advertisement
The GEMU 567 BioStar® Control Valve is designed to precisely control low flow rates of high purity fluids or gaseous media required in the pharmaceutical, biotech, health care, and food & beverage industries.
Features:
- Extremely compact design
- Sizes ¼”- ¾”
- ASME BPE tube weld and hygienic clamp ends
- Body wrought 316L stainless steel (ASTM A479) / (1.4435 BN2) with controlled sulfur .005 - .017%, others available upon request
- Surface finishes 20 Ra mechanical (SF1), 20 Ra electro-polish (SF5), and 15 Ra electro-polish (SF4)
- Manual or pneumatically operated
- Autoclavable
- Available with either linear or equal % flow characteristics
- Cv range .09 to 4.8 gpm
- Operating pressures 0 – 150 psig
- Operating temperatures 14° - 320° F
- Self-draining design for Clean-in-Place (CIP) and Steam-in-Place (SIP) systems
- Optional by-pass provides high flow velocities to facilitate cleaning
- Valve integration into custom block designs
- FDA CFR 177.1550 (PTFE), 177.2600 (Elastomers), and USP Class VI, <87>, <88> compliance
- 3A Certification available
- Animal Derived Component Free (ADCF)
Advertisement
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
What the Olanzapine Depot Approval Means for CMC Teams
3
Complying with International Pharmacopoeias
4
PharmTech AI Pulse Check: Availability Bias Threatens AI Regulatory Reviews
5